)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Marksans Pharma (MARKSANS) investor relations material
Marksans Pharma Q1 25/26 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.Q1 25/26 earnings summary13 Aug, 2025
Executive summary
Q1 FY26 revenue grew 5% year-over-year to INR 620 crores, driven by new product launches in the US and easing raw material costs, but profitability was impacted by nonrecurring factors such as integration expenses, ECL provision, and forex volatility.
Early signs of demand recovery are visible in Q2, with a focus on scaling capacity, operational efficiency, and new high-margin launches in the UK.
Board approved unaudited consolidated and standalone financial results for the quarter ended June 30, 2025, with statutory auditors issuing an unmodified review opinion.
Financial highlights
Operating revenue for Q1 FY26 was INR 620 crores, up 5% year-over-year from INR 590.6 crores; gross profit rose 8.9% year-over-year to INR 358.2 crores, with a gross margin of 57.8%.
US and North America revenue grew 30.6% year-over-year to INR 327.6 crores, driven by new launches; UK and EU revenue was INR 203.8 crores; Australia and New Zealand INR 57 crores; Rest of World INR 31.6 crores.
EBITDA was INR 100.1 crores, with a margin of 16.1%, down 560 bps year-over-year; net profit was INR 58.2 crores, down 34.7% year-over-year, impacted by one-time costs and forex losses.
Cash from operations was INR 48.7 crores; CapEx was INR 37.8 crores; R&D spend was INR 12.1 crores (2% of revenue); cash balance was INR 71.1 crores as of June 30, 2025.
Basic and diluted EPS for the quarter were INR 1.29 (consolidated) and INR 1.06 (standalone).
Outlook and guidance
Early Q2 shows demand recovery in the US, UK, and Australia, with expectations for sequential improvement in subsequent quarters.
Revenue target for FY26 is close to INR 3,000 crores, but may fall slightly short due to tariff uncertainties and global impacts; long-term goal is to double US revenue and become a top 5 OTC company in North America.
Margins are expected to improve quarter-on-quarter but remain flattish year-over-year due to ongoing pricing pressure in the UK.
Gross margins are expected to remain healthy, with further improvement anticipated from Q3 as product mix optimization continues.
How did foreign exchange impact other income?
What entities' results weren't reviewed?
Detail changes in consolidated inventories.
Explain the '26 U.K. business degrowth in detail.
Elaborate on gross margin improvement drivers.
Guidance for FY '27 revenue and margins?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Marksans Pharma earnings date
Q2 25/2612 Nov, 2025
Next Marksans Pharma earnings date
Q2 25/2612 Nov, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Edge3 Oct 2025
Epiroc: A Culture of Moving Mountains
From automation to electrification, Swedish industrial giant Epiroc is leading a transformation in how the world mines.
)
Company Research22 Sep 2025
Moody's: Shaping Global Credit
Explore Moody's evolution from publishing manuals to becoming a giant in credit ratings, guiding issuers, investors, and regulators worldwide.
Frequently asked questions
Marksans Pharma Limited is a pharmaceutical company engaged in the research, manufacturing, and marketing of generic pharmaceutical formulations. The company produces a wide range of dosage forms including tablets, capsules, liquids, and ointments across therapeutic areas such as pain management, gastrointestinal, cardiovascular, and anti-infective segments. It serves regulated and semi-regulated markets including the United States, Europe, Australia, and emerging regions. Marksans Pharma Limited operates manufacturing facilities compliant with global regulatory standards and offers contract manufacturing services. The company is headquartered in Mumbai, India, and its shares are listed on the BSE.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage